In recent years, immunotherapy, targeting the immune checkpoints, which include programmed cell death receptor 1 (PD-1), programmed cell death receptor-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), has a great effect on the treatment of NSCLC (2) and has improved the 5-year survival rate of advanced NSCLC from 4% to 15% (3, 4). This evidence concerns the gene CD274 and non-small cell lung carcinoma.